Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Full Text of this article
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Hogan, C. M.
space
  arrow  Hammer, S. M.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REVIEW

Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics*

right arrow Christine M. Hogan, MD, and Scott M. Hammer, MD

15 May 2001 | Volume 134 Issue 10 | Pages 978-996

The course of HIV infection varies widely among individuals. Immunologic and genetic studies of long-term nonprogressors and exposed yet uninfected persons have helped to elucidate the mechanisms by which some persons are protected from HIV acquisition or have slow rates of disease progression. This two-part review describes what is currently known about host factors in HIV-1 infection. Studies for inclusion were identified by a systematic search of PubMed for English-language literature published from 1988 through June 2000. Abstracts of presentations at major meetings convened in 2000 were also included if appropriate. The first part of the review discussed cellular and humoral immunity to HIV infection. This second part describes genetic host factors—namely, inheritance of mutant chemokine receptors or ligands, such as CCR5-{Delta}32, CCR2-V64I, stromal cell–derived factor-1 3'{alpha}, and CCR5 promoter polymorphisms, as well as HLA type—that affect susceptibility to infection and subsequent clinical course. Soluble inhibitory factors, the cytokine milieu, and concomitant infections also affect outcome. Knowledge of host responses is increasingly being applied to new therapeutic strategies, including early treatment, immune modulation, structured treatment interruptions, therapeutic vaccination, and new chemotherapeutic agents, as well as to vaccine development.

Author and Article Information
space

From Columbia University College of Physicians and Surgeons, New York, New York.

Part 1 of this review was published in the 1 May 2001 issue.

Acknowledgment: The authors thank Brian-Fred Fitzsimmons, MD, for assistance with preparation of the figures.

Grant Support: Dr. Hammer is supported by grants AI46386 and AI48013 from the National Institute of Allergy and Infectious Diseases. Dr. Hogan is supported in part by Center for AIDS Research grant 5P30AI42848-03 from the National Institute of Health and the National Institute of Allergy and Infectious Diseases and in part by the SmithKline Beecham Development Partners Junior Faculty Award.

Requests for Single Reprints: Christine M. Hogan, MD, Division of Infectious Diseases, Columbia University, College of Physicians and Surgeons, P & S Box 82, 630 West 168th Street, New York, NY 10032; e-mail, ch358{at}columbia.edu.

Current Author Addresses: Drs. Hogan and Hammer: Division of Infectious Diseases, Columbia University, College of Physicians and Surgeons, P & S Box 82, 630 West 168th Street, New York, NY 10032.




This article has been cited by other articles:


Home page
J. Gen. Virol.Home page
G. Bello, C. Casado, V. Sandonis, M. Alonso-Nieto, J. L. Vicario, S. Garcia, V. Hernando, C. Rodriguez, J. d. Romero, and C. Lopez-Galindez
A subset of human immunodeficiency virus type 1 long-term non-progressors is characterized by the unique presence of ancestral sequences in the viral population
J. Gen. Virol., February 1, 2005; 86(2): 355 - 364.
[Abstract] [Full Text] [PDF]


Home page
Stat Methods Med ResHome page
M. G Hudgens, P. B Gilbert, and S. G Self
Endpoints in vaccine trials
Statistical Methods in Medical Research, April 1, 2004; 13(2): 89 - 114.
[Abstract] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
H. Kan, Z. Xie, and M. S. Finkel
p38 MAP kinase-mediated negative inotropic effect of HIV gp120 on cardiac myocytes
Am J Physiol Cell Physiol, January 1, 2004; 286(1): C1 - C7.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
T. B. Campbell, K. Schneider, T. Wrin, C. J. Petropoulos, and E. Connick
Relationship between In Vitro Human Immunodeficiency Virus Type 1 Replication Rate and Virus Load in Plasma
J. Virol., November 15, 2003; 77(22): 12105 - 12112.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
J. B. Alimonti, T. B. Ball, and K. R. Fowke
Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS
J. Gen. Virol., July 1, 2003; 84(7): 1649 - 1661.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Oxenius, D. A. Price, H. F. Gunthard, S. J. Dawson, C. Fagard, L. Perrin, M. Fischer, R. Weber, M. Plana, F. Garcia, et al.
Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection
PNAS, October 15, 2002; 99(21): 13747 - 13752.
[Abstract] [Full Text] [PDF]




 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2001 by the American College of Physicians.